MCID: PSR016
MIFTS: 41

Psoriatic Juvenile Idiopathic Arthritis

Categories: Bone diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Psoriatic Juvenile Idiopathic Arthritis

MalaCards integrated aliases for Psoriatic Juvenile Idiopathic Arthritis:

Name: Psoriatic Juvenile Idiopathic Arthritis 52 71
Psoriasis-Related Juvenile Idiopathic Arthritis 52 58 17
Juvenile Psoriatic Arthritis 52 58 71
Psoriasis-Related Jia 52 58
Juvenile Arthritis 71

Characteristics:

Orphanet epidemiological data:

58
psoriasis-related juvenile idiopathic arthritis
Age of onset: Childhood; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare respiratory diseases
Rare systemic and rhumatological diseases


External Ids:

ICD10 via Orphanet 33 L40.5+ M09.0*
UMLS via Orphanet 72 C0409672
Orphanet 58 ORPHA85436
UMLS 71 C3495559 C3714758 C3890176

Summaries for Psoriatic Juvenile Idiopathic Arthritis

NIH Rare Diseases : 52 Psoriatic juvenile idiopathic arthritis is a subtype of juvenile idiopathic arthritis that is characterized by both arthritis and psoriasis . Other signs and symptoms may include dactylitis (inflammation and swelling of an entire finger or toe); nail pitting or splitting; and eye problems. Although the underlying cause of psoriatic juvenile idiopathic arthritis is currently unknown (idiopathic), it is thought to occur due to a combination of genetic and environmental factors . It is very rare for more than one member of a family to have juvenile arthritis; however, research suggests that having a family member with juvenile arthritis or any autoimmune disease may increase the risk of having juvenile arthritis, in general. Treatment usually involves different types of medications to help manage symptoms and/or physical therapy .

MalaCards based summary : Psoriatic Juvenile Idiopathic Arthritis, also known as psoriasis-related juvenile idiopathic arthritis, is related to hereditary periodic fever syndrome and exanthem. An important gene associated with Psoriatic Juvenile Idiopathic Arthritis is MEFV (MEFV Innate Immuity Regulator, Pyrin), and among its related pathways/superpathways are NOD-like receptor signaling pathway and Yersinia infection. The drugs Methotrexate and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include eye, bone and liver, and related phenotypes are abnormality of tumor necrosis factor secretion and arthralgia

Related Diseases for Psoriatic Juvenile Idiopathic Arthritis

Diseases related to Psoriatic Juvenile Idiopathic Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 68, show less)
# Related Disease Score Top Affiliating Genes
1 hereditary periodic fever syndrome 29.9 NLRP3 MEFV
2 exanthem 29.8 NLRP3 MEFV
3 arthritis 29.5 PSTPIP1 NOD2 MEFV
4 familial mediterranean fever 28.2 PSTPIP1 NOD2 NLRP3 MEFV
5 juvenile rheumatoid arthritis 11.9
6 pustulosis of palm and sole 10.5
7 psoriasis 10.5
8 psoriatic arthritis 10.2
9 spondyloarthropathy 1 10.2
10 inflammatory spondylopathy 10.2
11 spondylitis 10.2
12 juvenile ankylosing spondylitis 10.1
13 arthropathy 10.1
14 uveitis 10.0
15 rheumatic disease 10.0
16 synovitis 10.0
17 tenosynovitis 10.0
18 erysipeloid 10.0 PSTPIP1 MEFV
19 arthritis, sacroiliac 9.9
20 autoimmune disease 9.9
21 celiac disease 1 9.9
22 osteoid osteoma 9.9
23 branchiootic syndrome 1 9.9
24 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.9
25 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.9
26 hydrops, lactic acidosis, and sideroblastic anemia 9.9
27 autosomal recessive disease 9.9
28 sensorineural hearing loss 9.9
29 renal hypertension 9.9
30 glomerulonephritis 9.9
31 inner ear disease 9.9
32 acute kidney failure 9.9
33 skin disease 9.9
34 iridocyclitis 9.9
35 autoimmune inner ear disease 9.9
36 polyarticular juvenile idiopathic arthritis 9.9
37 wells syndrome 9.9 NLRP3 MEFV
38 erysipelas 9.9 PSTPIP1 MEFV
39 familial cold autoinflammatory syndrome 2 9.9 NLRP3 MEFV
40 familial cold autoinflammatory syndrome 1 9.9 NLRP3 MEFV
41 cervical adenitis 9.9 NLRP3 MEFV
42 chronic meningitis 9.8 NLRP3 MEFV
43 neurofibromatosis, type ii 9.8 PSTPIP1 MEFV
44 pharyngitis 9.8 NLRP3 MEFV
45 peroxisomal disease 9.8 NLRP3 MEFV
46 aphthous stomatitis 9.8 NLRP3 MEFV
47 stomatitis 9.8 NLRP3 MEFV
48 proteasome-associated autoinflammatory syndrome 1 9.7 NLRP3 MEFV
49 sapho syndrome 9.7 PSTPIP1 NOD2
50 gout 9.7 NLRP3 MEFV
51 osteomyelitis 9.7 NOD2 NLRP3
52 peritonitis 9.6 NLRP3 MEFV
53 primary bacterial infectious disease 9.6 NOD2 MEFV
54 mental retardation, autosomal dominant 24 9.5 PSTPIP1 NLRP3 MEFV
55 chronic recurrent multifocal osteomyelitis 9.5 PSTPIP1 NLRP3 MEFV
56 sebaceous gland disease 9.5 PSTPIP1 NLRP3 MEFV
57 amyloidosis 9.4 NLRP3 MEFV
58 crohn's disease 9.3 NOD2 NLRP3
59 mevalonic aciduria 8.9 PSTPIP1 NOD2 NLRP3 MEFV
60 muckle-wells syndrome 8.9 PSTPIP1 NOD2 NLRP3 MEFV
61 pyoderma 8.9 PSTPIP1 NOD2 NLRP3 MEFV
62 pyoderma gangrenosum 8.9 PSTPIP1 NOD2 NLRP3 MEFV
63 periodic fever, familial, autosomal dominant 8.9 PSTPIP1 NOD2 NLRP3 MEFV
64 blau syndrome 8.9 PSTPIP1 NOD2 NLRP3 MEFV
65 familial cold autoinflammatory syndrome 8.9 PSTPIP1 NOD2 NLRP3 MEFV
66 cinca syndrome 8.9 PSTPIP1 NOD2 NLRP3 MEFV
67 behcet syndrome 8.9 PSTPIP1 NOD2 NLRP3 MEFV
68 inflammatory bowel disease 8.8 PSTPIP1 NOD2 NLRP3 MEFV

Graphical network of the top 20 diseases related to Psoriatic Juvenile Idiopathic Arthritis:



Diseases related to Psoriatic Juvenile Idiopathic Arthritis

Symptoms & Phenotypes for Psoriatic Juvenile Idiopathic Arthritis

Human phenotypes related to Psoriatic Juvenile Idiopathic Arthritis:

58 31 (showing 28, show less)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of tumor necrosis factor secretion 58 31 hallmark (90%) Very frequent (99-80%) HP:0011118
2 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
3 pruritus 58 31 frequent (33%) Frequent (79-30%) HP:0000989
4 psoriasiform dermatitis 58 31 frequent (33%) Frequent (79-30%) HP:0003765
5 nail pits 58 31 frequent (33%) Frequent (79-30%) HP:0001803
6 antinuclear antibody positivity 58 31 frequent (33%) Frequent (79-30%) HP:0003493
7 polyarticular arthritis 58 31 frequent (33%) Frequent (79-30%) HP:0005764
8 enthesitis 58 31 frequent (33%) Frequent (79-30%) HP:0100686
9 oligoarthritis 58 31 frequent (33%) Frequent (79-30%) HP:0040313
10 finger dactylitis 58 31 frequent (33%) Frequent (79-30%) HP:0031090
11 toe dactylitis 58 31 frequent (33%) Frequent (79-30%) HP:0031091
12 reduced visual acuity 58 31 occasional (7.5%) Occasional (29-5%) HP:0007663
13 abnormality of the knee 58 31 occasional (7.5%) Occasional (29-5%) HP:0002815
14 abnormality of the shoulder 58 31 occasional (7.5%) Occasional (29-5%) HP:0003043
15 psoriasiform lesion 58 31 occasional (7.5%) Occasional (29-5%) HP:0025526
16 abnormality of the wrist 58 31 occasional (7.5%) Occasional (29-5%) HP:0003019
17 malar rash 58 31 occasional (7.5%) Occasional (29-5%) HP:0025300
18 generalized morning stiffness 58 31 occasional (7.5%) Occasional (29-5%) HP:0005197
19 abnormality of the temporomandibular joint 58 31 very rare (1%) Very rare (<4-1%) HP:0010754
20 onycholysis 58 31 very rare (1%) Very rare (<4-1%) HP:0001806
21 iritis 58 31 very rare (1%) Very rare (<4-1%) HP:0001101
22 iridocyclitis 58 31 very rare (1%) Very rare (<4-1%) HP:0001094
23 sacroiliac arthritis 58 31 very rare (1%) Very rare (<4-1%) HP:0012317
24 skin rash 58 Occasional (29-5%)
25 limitation of joint mobility 58 Occasional (29-5%)
26 autoimmunity 58 Frequent (79-30%)
27 uveitis 58 Occasional (29-5%)
28 anterior uveitis 58 Occasional (29-5%)

MGI Mouse Phenotypes related to Psoriatic Juvenile Idiopathic Arthritis:

45 (showing 2, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.26 MEFV NLRP3 NOD2 PSTPIP1
2 immune system MP:0005387 8.92 MEFV NLRP3 NOD2 PSTPIP1

Drugs & Therapeutics for Psoriatic Juvenile Idiopathic Arthritis

Drugs for Psoriatic Juvenile Idiopathic Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 71, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
2
leucovorin Approved Phase 4 58-05-9 6006 143
3
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
4
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
5
Etanercept Approved, Investigational Phase 4 185243-69-0
6
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
7
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
8 Immunologic Factors Phase 4
9 Immunosuppressive Agents Phase 4
10 Folic Acid Antagonists Phase 4
11 Vitamin B Complex Phase 4
12 Dermatologic Agents Phase 4
13 Folate Phase 4
14 Antimetabolites Phase 4
15 Antirheumatic Agents Phase 4
16 Vitamin B9 Phase 4
17 Cyclooxygenase 2 Inhibitors Phase 4
18 Analgesics, Non-Narcotic Phase 4
19 Analgesics Phase 4
20 Cyclooxygenase Inhibitors Phase 4
21 Anti-Inflammatory Agents, Non-Steroidal Phase 4
22 Vaccines Phase 4
23 Liver Extracts Phase 4
24 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
25
Adalimumab Approved Phase 2, Phase 3 331731-18-1 16219006
26
Infliximab Approved Phase 2, Phase 3 170277-31-3
27
Tofacitinib Approved, Investigational Phase 3 477600-75-2
28
Certolizumab pegol Approved Phase 3 428863-50-7
29 Anti-Inflammatory Agents Phase 2, Phase 3
30 Gastrointestinal Agents Phase 2, Phase 3
31 Antineoplastic Agents, Immunological Phase 2, Phase 3
32 Pharmaceutical Solutions Phase 3
33 Protein Kinase Inhibitors Phase 3
34 Antibodies, Monoclonal Phase 3
35 Antibodies Phase 3
36 Immunoglobulins Phase 3
37 Hormones Phase 3
38 Mitogens Phase 3
39
Prednisolone Approved, Vet_approved Phase 1 50-24-8 5755
40
Methylprednisolone Approved, Vet_approved Phase 1 83-43-2 6741
41
Methylprednisolone hemisuccinate Approved Phase 1 2921-57-5
42 Prednisolone acetate Approved, Vet_approved Phase 1 52-21-1
43
Prednisolone phosphate Approved, Vet_approved Phase 1 302-25-0
44
Prednisolone hemisuccinate Experimental Phase 1 2920-86-7
45 Methylprednisolone Acetate Phase 1
46 Protective Agents Phase 1
47 Neuroprotective Agents Phase 1
48 glucocorticoids Phase 1
49 Antineoplastic Agents, Hormonal Phase 1
50 Antiemetics Phase 1
51 Hormone Antagonists Phase 1
52 Autonomic Agents Phase 1
53 Interleukin 1 Receptor Antagonist Protein Phase 1
54
Ondansetron Approved 99614-02-5 4595
55
Levoleucovorin Approved, Investigational 68538-85-2
56
Acetaminophen Approved 103-90-2 1983
57 Antibodies, Antinuclear
58 Hypolipidemic Agents
59 Evening Primrose
60 Lipid Regulating Agents
61 Neurotransmitter Agents
62 Tranquilizing Agents
63 Antipsychotic Agents
64 Psychotropic Drugs
65 Serotonin Agents
66 Central Nervous System Depressants
67 Serotonin Antagonists
68 Anti-Anxiety Agents
69 Antipruritics
70
Evening primrose oil Investigational, Nutraceutical 308064-97-3
71
Serotonin Investigational, Nutraceutical 50-67-9 5202

Interventional clinical trials:

(showing 48, show less)
# Name Status NCT ID Phase Drugs
1 A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis. Completed NCT00807846 Phase 4 Celecoxib;Naproxen
2 Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA Completed NCT00792233 Phase 4
3 Trial of Early Aggressive Therapy in Juvenile Idiopathic Arthritis (TREAT in JIA) Completed NCT00443430 Phase 4 methotrexate;methotrexate - etanercept - prednisolone arm
4 A Phase IV Study to Evaluate Decreased Dose Frequency in Patients With Systemic Juvenile Arthritis (SJIA) Who Experience Laboratory Abnormalities During Treatment With Tocilizumab Completed NCT01734382 Phase 4 Tocilizumab
5 Multicenter Randomized Clinical Trial in Patients With Juvenile Idiopathic Arthritis: Safety and Efficacy of Vaccination With Live Attenuated Measles, Mumps, Rubella Vaccine Completed NCT00731965 Phase 4
6 Short and Long-term Immunogenicity and Safety Following the 23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy Completed NCT02196480 Phase 4
7 Randomized, Double-Blind, Multicenter, Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA Completed NCT00652925 Phase 3 Celecoxib;Celecoxib;Naproxen
8 ANAkinra in Severe Juvenile Idiopathic Arthritis of Systemic Onset (ANAJIS) Completed NCT00339157 Phase 2, Phase 3 Anakinra
9 EFFICACY, SAFETY AND TOLERABILITY OF TOFACITINIB FOR TREATMENT OF POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (JIA) IN CHILDREN AND ADOLESCENT SUBJECTS Completed NCT02592434 Phase 3 CP-690,550 (tofacitinib)
10 Efficacy, Safety, and Tolerability of Infliximab (Remicade; Schering-Plough) in Juvenile Spondyloarthropathies: a Three-Month, Randomized, Double-Blind, Placebo-Controlled Trial and 52-Week Open Extension. Completed NCT00591201 Phase 2, Phase 3 infliximab;Placebo
11 Evaluation of the Efficacy of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis: Randomized Double-blind Placebo-controlled Trial Completed NCT01385826 Phase 2, Phase 3 Anti-tumor necrosis factor alpha monoclonal antibody;placebo
12 An Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Efficacy, Safety and Tolerability up to 4 Years in Patients With Juvenile Idiopathic Arthritis Subtypes of Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis Recruiting NCT03769168 Phase 3 AIN457
13 A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA) Recruiting NCT03773978 Phase 3 Baricitinib;Placebo
14 A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA) Recruiting NCT03773965 Phase 3 Baricitinib
15 A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) Recruiting NCT01500551 Phase 3 Tofacitinib;Tofacitinib
16 A Three-part Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Secukinumab Treatment in Juvenile Idiopathic Arthritis Subtypes of Psoriatic and Enthesitis-related Arthritis Active, not recruiting NCT03031782 Phase 3 AIN457
17 A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA) Active, not recruiting NCT01550003 Phase 3 Certolizumab Pegol (CZP)
18 A Multicenter, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab, a Humanized Anti-TNFa Antibody, in Subjects With Active Polyarticular Juvenile Idiopathic Arthritis (JIA) Despite Standard Therapy Terminated NCT01230827 Phase 3 CNTO 148 (Golimumab);Placebo;Methotrexate
19 Prevention of Retarded Growth by Early Treatment With Recombinant Human Growth Factor Genotonorm (Registered) in Children With Systemic Forms of Chronic Juvenile Arthritis Receiving Long-term Corticosteroid Therapy. Extension of the Study Beyond Three Years Terminated NCT00174291 Phase 3 Somatropin
20 The Effect of Vigorous Exercise on Motor Function and Functional Fitness in Juvenile Arthritis Completed NCT00213187 Phase 2
21 An Open-label Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Tolerability Of CP-690,550 In Pediatric Patients From 2 To Less Than 18 Years Of Age With Juvenile Idiopathic Arthritis (JIA) Completed NCT01513902 Phase 1 CP-690,550;CP-690,550;CP-690,550
22 Randomized Placebo Controlled Trial of Subcutaneous rhIL-1A (Anakinra) in the Management of Hospitalized Pediatric and Adult Patients With Macrophage Activation Syndrome Recruiting NCT02780583 Phase 1 kineret;placebo
23 Usefulness of Protoarray®Microarray for Identifying Biomarkers in Idiopathic Juvenile Arthritis Antinuclear Antibodies Positive. Unknown status NCT02343770
24 Research Registry for Juvenile Arthritis Unknown status NCT00090571
25 ARTEMIS Synovial Markers in Arthritis Childhood Completed NCT02505828
26 Humira® for Subcutaneous Injection Special Investigation ( All-case Survey ) in Patients With Juvenile Idiopathic Arthritis Study Completed NCT01412021
27 LCS® PS: A Prospective, Multi-center Clinical Investigation of the LCS® Complete Posterior Stabilized Mobile-bearing Total Knee System Completed NCT00487565
28 Determination of the Effective Individual Dose of Etanercept in Patients Treated for Juvenile Idiopathic Arthritis Completed NCT02030613
29 Study of Gammalinolenic Acid for Juvenile Rheumatoid Arthritis Completed NCT00004420 gamma-Linolenic acid
30 Jointstrong Intervention for Juvenile Arthritis Completed NCT01166750
31 C.O.R.P.U.S. : Observational Cohort of Active Rheumatoid Arthritis, Spondylarthropathy and Idiopathic Juvenile Arthritis in France Completed NCT02886689 TNF-alpha antagonist and other biotherapy
32 High Resolution Infrared Thermographic Imaging as a Diagnostic Aid for Acute Undifferentiated Limp in Children. Completed NCT03312348
33 Start Time Optimization of Biologics in Polyarticular JIA Completed NCT02593006
34 Multicenter, Diagnostic and Prospective Study to Differentiate Child Septic and Inflammatory Arthritis by Comparative Analysis Recruiting NCT03827759
35 Fertility Study of Women With Chronic Inflammatory Rheumatism Recruiting NCT03452735
36 Treatment With Specific Carbohydrate Diet in Children With Juvenile Idiopathic Arthritis Recruiting NCT04205500
37 iCanCope With Pain: Usability and Feasibility Testing of a Smartphone Application to Manage Pain in Youth With Arthritis Recruiting NCT02764346
38 The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis Recruiting NCT04169828 Methotrexate;Ondansetron
39 The Development and Validation of Quantitative Imaging Biomarkers as a Measure of Disease Activity in Juvenile Idiopathic Arthritis Recruiting NCT02684695
40 Prospective Multi-Center Observational Study to Assess Persistence, Adherence and Changes in Disease Activity in the Children Population of Juvenile Arthritis Patients Treated With Adalimumab (HUMIRA) in the Routine Clinical Settings in the Russian Federation (PETITE) Active, not recruiting NCT03383263
41 A Long-term, Multi-center, Longitudinal Post-marketing, Observational Study to Assess Long Term Safety and Effectiveness of HUMIRA® (Adalimumab) in Children With Moderately to Severely Active Polyarticular or Polyarticular-course Juvenile Idiopathic Arthritis (JIA) - STRIVE Active, not recruiting NCT00783510 Methotrexate
42 Prediction of Temporomandibular Involvement in Juvenile Idiopathic Arthritis Active, not recruiting NCT02218892
43 Human Papilloma Virus Vaccination and Chronic Inflammatory Rheumatic Disease. A Cross-sectional Study of Vaccinal Coverage, Barriers and Motivations. Not yet recruiting NCT04180228
44 Chronic Non-inflammatory Pains in Rheumatopediatrics Not yet recruiting NCT03740347
45 Massage Therapy for Children With Juvenile Idiopathic Arthritis Experiencing Pain: a Pilot Randomized Controlled Trial Terminated NCT02218580
46 Reducing Problematic Substance Use in Youth With Chronic Medical Conditions Withdrawn NCT01709201
47 The Effect of Whole Body Vibration Therapy on Muscle Function and Joint Loading in Children With Juvenile Idiopathic Arthritis Withdrawn NCT00836394
48 Pilot Study: Ultrasound Assessment of Steroid Joint Injections in Juvenile Idiopathic Arthritis Withdrawn NCT01114243

Search NIH Clinical Center for Psoriatic Juvenile Idiopathic Arthritis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aurothioglucose
Diclofenac
Diclofenac Potassium
Diclofenac Sodium
Etanercept
Ibuprofen
Methotrexate
Methotrexate Sodium
Naproxen
Naproxen sodium
oxaprozin
solufenum
Sulfasalazine
tocilizumab
Tolmetin
Tolmetin Sodium

Genetic Tests for Psoriatic Juvenile Idiopathic Arthritis

Anatomical Context for Psoriatic Juvenile Idiopathic Arthritis

MalaCards organs/tissues related to Psoriatic Juvenile Idiopathic Arthritis:

40
Eye, Bone, Liver, Skin, Testes

Publications for Psoriatic Juvenile Idiopathic Arthritis

Articles related to Psoriatic Juvenile Idiopathic Arthritis:

(showing 4, show less)
# Title Authors PMID Year
1
Enthesitis as a component of dactylitis in psoriatic juvenile idiopathic arthritis: histology of an established clinical entity. 61
25774101 2015
2
Psoriatic juvenile idiopathic arthritis associated with uveitis: a case report. 61
24191219 2013
3
Psoriatic juvenile idiopathic arthritis: a tale of two subgroups. 61
21709556 2011
4
Autoinflammatory genes and susceptibility to psoriatic juvenile idiopathic arthritis. 61
18576390 2008

Variations for Psoriatic Juvenile Idiopathic Arthritis

Expression for Psoriatic Juvenile Idiopathic Arthritis

Search GEO for disease gene expression data for Psoriatic Juvenile Idiopathic Arthritis.

Pathways for Psoriatic Juvenile Idiopathic Arthritis

GO Terms for Psoriatic Juvenile Idiopathic Arthritis

Cellular components related to Psoriatic Juvenile Idiopathic Arthritis according to GeneCards Suite gene sharing:

(showing 1, show less)
# Name GO ID Score Top Affiliating Genes
1 lamellipodium GO:0030027 8.62 PSTPIP1 MEFV

Biological processes related to Psoriatic Juvenile Idiopathic Arthritis according to GeneCards Suite gene sharing:

(showing 13, show less)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.67 PSTPIP1 NOD2 NLRP3 MEFV
2 inflammatory response GO:0006954 9.61 PSTPIP1 NLRP3 MEFV
3 cellular response to lipopolysaccharide GO:0071222 9.52 NOD2 NLRP3
4 defense response GO:0006952 9.51 NOD2 NLRP3
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.49 NOD2 NLRP3
6 negative regulation of inflammatory response GO:0050728 9.48 NLRP3 MEFV
7 regulation of inflammatory response GO:0050727 9.46 NOD2 NLRP3
8 innate immune response GO:0045087 9.46 PSTPIP1 NOD2 NLRP3 MEFV
9 positive regulation of interleukin-1 beta secretion GO:0050718 9.4 NOD2 NLRP3
10 cellular response to peptidoglycan GO:0071224 9.32 NOD2 NLRP3
11 positive regulation of type 2 immune response GO:0002830 9.26 NOD2 NLRP3
12 cytokine secretion involved in immune response GO:0002374 8.96 NOD2 NLRP3
13 detection of biotic stimulus GO:0009595 8.62 NOD2 NLRP3

Molecular functions related to Psoriatic Juvenile Idiopathic Arthritis according to GeneCards Suite gene sharing:

(showing 2, show less)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.13 PSTPIP1 NLRP3 MEFV
2 peptidoglycan binding GO:0042834 8.62 NOD2 NLRP3

Sources for Psoriatic Juvenile Idiopathic Arthritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....